Immune Thrombocytopenia is a rare autoimmune bleeding disorder, caused by various etiologies. The main characteristic of the diseases is the defects in the production of platelets, and their increased destruction, which finally result in an overall decreased platelet count. The disequilibrium between the rates of platelet production and destruction in the bone marrow results in varying degrees of risk of bleeding.
The guidelines recommend the use of corticosteroid as the main therapy, which results in the reduction of the autoantibodies production against platelets and megakaryocytes, with a decreased tendency of bleeding.
Understanding, diagnosing, and treating patients with Immune Thrombocytopenia require expertise in the rapidly growing field of autoimmune disorders and research has been concentrated in the finding of novel treatment for this disease.
A lot of advances have been made in the use of thrombopoietin receptor agonists (TPO-RAs), which are used to treat thrombocytopenia at different disease states and have an important role in first-line therapy.
However, there is still a growing need to find alternative therapies which will improve the long-term response and reduce the relapse rate.
In this Research Topic, we would like to collect the recent advances on the management of Immune Thrombocytopenia, with a focus on the use of TOP-RAs and particular emphasis on new treatments for the disease.
Authors are welcome to submit reviews, original research, and other article types on the following themes:
• Current TPO-RAs treatments for Immune Thrombocytopenia
• Emerging treatments in the management of Immune Thrombocytopenia
• Emergency treatment of Immune Thrombocytopenia
• Diagnosis of Immune Thrombocytopenia
Immune Thrombocytopenia is a rare autoimmune bleeding disorder, caused by various etiologies. The main characteristic of the diseases is the defects in the production of platelets, and their increased destruction, which finally result in an overall decreased platelet count. The disequilibrium between the rates of platelet production and destruction in the bone marrow results in varying degrees of risk of bleeding.
The guidelines recommend the use of corticosteroid as the main therapy, which results in the reduction of the autoantibodies production against platelets and megakaryocytes, with a decreased tendency of bleeding.
Understanding, diagnosing, and treating patients with Immune Thrombocytopenia require expertise in the rapidly growing field of autoimmune disorders and research has been concentrated in the finding of novel treatment for this disease.
A lot of advances have been made in the use of thrombopoietin receptor agonists (TPO-RAs), which are used to treat thrombocytopenia at different disease states and have an important role in first-line therapy.
However, there is still a growing need to find alternative therapies which will improve the long-term response and reduce the relapse rate.
In this Research Topic, we would like to collect the recent advances on the management of Immune Thrombocytopenia, with a focus on the use of TOP-RAs and particular emphasis on new treatments for the disease.
Authors are welcome to submit reviews, original research, and other article types on the following themes:
• Current TPO-RAs treatments for Immune Thrombocytopenia
• Emerging treatments in the management of Immune Thrombocytopenia
• Emergency treatment of Immune Thrombocytopenia
• Diagnosis of Immune Thrombocytopenia
